

15 August 2024

# Mernova Q3 Revenue Update

## **Highlights:**

- \$2.1m (C\$1.9m) in confirmed unaudited purchase orders for delivery in Q3 2024
- Surpasses Q2 2024 unaudited confirmed purchase orders of \$2.0m (C\$1.8m), which were a 25% increase on Q1 2024 (\$1.6m), and a 33% increase on Q2 2023 (\$1.5m)
- Mernova was a strong contributor to group H1 2024 revenues of \$9.2m, a 31% increase on H1 2023 and annualised rate of \$18.4m
- Other qualitative achievements including new product listings, and strong cultivation yields

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues its strong performance with \$2.1m (C\$1.9) in unaudited confirmed purchase orders to date in Q3 2023. These figures surpass Q2 2024, when Mernova had confirmed unaudited purchase orders of \$2.0m (C\$1.8m). Q2 2024 figures were a 25% increase on Q1 2024 (\$1.6m) and a 33% increase on Q2 2023 (\$1.5m). During H1 2024, Mernova revenues supported group revenues of \$9.2m, a 31% increase on H1 2023 and an annualised rate of \$18.4m.

In addition to the revenue performance, the Company also listed two new holidays SKUs in most provinces:

- Mistletoke Variety Pack 2x0.5g Black Mamba pre rolls, 2x0.5g French Cookie pre rolls and 2x0.5 Blue Pave pre rolls
- Pave Holiday 12 Days of Christmas 6x0.5g Blue Pave pre rolls and 6x0.5g Candy Pave pre rolls

Mernova also achieved strong yields for multiple strains, due to performining process changes in grow cycles:

- French Cookies batch B13 yielded 53.7 Kg (a record) vs. average French Cookies yield of 40 Kg
- Black Mamba batch B54 yielded 46.2 Kg vs. average Black Mamba yield of 39 Kg

## Management commentary:

**CEO and Managing Director, Mr William Lay said:** "I am very proud of the entire team at Mernova for their ongoing progress. Sales continue to be very strong, indicating the market demand for high quality products. I am also pleased by the tenacity of Mernova's management, whether with respect to relentless efforts to bring new products to market, or iterating the grow cycle to produce higher yields."

#### -Ends-

#### **Authority and Contact Details**

This announcement has been authorised for release by the CEO and MD of Melodiol Global Health Limited. For further information, please contact:

#### **Investor Enquiries**

Melodiol Global Health Limited E: <u>info@cresopharma.com</u> P: +61 (0) 497 571 532

ABN: 89 609 406 911



#### **About Melodiol**

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <a href="https://melodiolglobalhealth.com/">https://melodiolglobalhealth.com/</a>

#### **Melodiol offices:**

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, BON 2TO and 50 Ivey Ln, Windsor, Nova Scotia, BON 2TO

### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.